Antifungal Activity of Baicalein Against Candida krusei Does Not Involve Apoptosis

Mycopathologia

Volumn 170, Issue 6, 2010, Pages 391-396

  Kang, Kai ^a   Fong, Wing Ping ^a   Tsang, Paul Wai Kei ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Baicalein; Candidakrusei; Mitochondrial membrane potential; Reactive oxygen species

Indexed keywords

CANDIDA ALBICANS; ISSATCHENKIA ORIENTALIS;

EID: 78049344946     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9341-2     Document Type: Article

References (38)

1. Samaranayake LP, MacFarlane TW. Oral candidosis. Bristol, United Kingdom: Wright; 1990.
2. Corner BE, Magee PT. Candida pathogenesis: unraveling the threads of infection. Curr Biol. 1997; 7: R691-4.
3. Krcmery V, Barnes AJ. Non-albicansCandida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002; 50: 243-60.
4. Kang K, Wong KS, Seneviratne CJ, Samaranayake LP, Fong WP, Tsang PWK. In vitro synergistic effects of metergoline and antifungal agents against Candidakrusei. Mycoses. 2009;. doi: 10. 1111/j. 1439-0507. 2009. 01747. x.
5. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, et al. Global Antifungal Surveillance Group. Candidakrusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol. 2008; 46: 515-21.
6. Muñoz P, Sánchez-Somolinos M, Alcalá L, Rodríguez-Créixems M, Peláez T, Bouza E. Candidakrusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother. 2005; 55: 188-93.
7. Katiyar SK, Edlind TD. Identification and expression of multidrug resistance-related ABC transporter genes in Candidakrusei. Med Mycol. 2001; 39: 109-16.
8. Lamping E, Ranchod A, Nakamura K, Tyndall JDA, Niimi K, Holmes AR, et al. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candidakrusei. Antimicrob Agents Chemother. 2009; 53: 354-69.
9. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Caspofungin Invasive Candidiasis Study Group, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347: 2020-9.
10. Pelletier R, Alarie I, Lagacé R, Walsh TJ. Emergence of disseminated candidiasis caused by Candidakrusei during treatment with caspofungin: case report and review of literature. Med Mycol. 2005; 43: 559-64.
11. Conen A, Weisser M, Jörg CO, Battegay M, Trampuz A, Frei R, et al. Candidakrusei-a serious complication in patients with hematological malignancies: successful treatment with caspofungin. Transpl Infect Dis. 2008; 10: 66-70.
12. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Arch Intern Med. 2000; 160: 2659-64.
13. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 2002; 40: 3551-7.
14. Blaszczyk T, Krzyzanowska J, Lamer-Zarawska E. Screening for antimycotic properties of 56 traditional Chinese drugs. Phytother Res. 2000; 14: 210-2.
15. Shieh DE, Liu LT, Lin CC. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000; 20: 2861-5.
16. van Leyen K, Arai K, Jin G, Kenyon V, Gerstner B, Rosenberg PA, et al. Novel lipoxygenase inhibitors as neuroprotective reagents. J Neurosci Res. 2008; 86: 904-9.
17. Yang D, Hu H, Huang S, Chaumont JP, Millet J. Study on the inhibitory activity, in vitro, of baicalein and baicalin against skin fungi and bacteria. Zhong Yao Cai. 2000; 23: 272-4.
18. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience. 2007; 150: 585-91.
19. Ono K, Nakane H, Fukushima M, Chermann JC, Barré-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem. 1990; 5: 469-76.
20. Wong KS, Tsang PWK. In vitro antifungal activity of aqueous extract of Scutellariabaicalensis Georgi root against Candidaalbicans. Int J Antimicrob Agents. 2009; 34: 284-5.
21. Cao YY, Dai BD, Wang Y, Huang S, Xu YG, Cao YB, et al. In vitro activity of baicalein against Candidaalbicans biofilms. Int J Antimicrob Agents. 2008; 32: 73-7.
22. Huang S, Cao YY, Dai BD, Sun XR, Zhu ZY, Cao YB, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candidaalbicans resistant to fluconazole. Biol Pharm Bull. 2008; 31: 2234-6.
23. Dai BD, Cao YY, Huang S, Xu YG, Gao PH, Wang Y, et al. Baicalein induces programmed cell death in Candidaalbicans. J Microbiol Biotechnol. 2009; 19: 803-9.
24. National Committee for Clinical Laboratory Standards, approved standard M27-A2, National Committee for Clinical Laboratory Standard, Wayne, PA. 2005.
25. Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Rodríguez-Tudela JL. Influence of glucose supplementation and inoculums size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol. 2001; 39: 525-32.
26. Kustimur S, Kalkanci A, Mansuroglu H, Senel K. Evaluation of the disc diffusion method with a comparison study for fluconazole susceptibility of Candida strains. Chin Med J. 2003; 116: 633-6.
27. Pina-Vaz C, Sansonetty F, Rodrigues AG, Costa-Oliveira S, Tavares C, Martinez-de-Oliveira J. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect. 2001; 7: 609-18.
28. Kobayashi D, Kondo K, Uehara N, Otokozawa S, Tsuji N, Yagihashi A, et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob Agents Chemother. 2002; 46: 3113-7.
29. Shirtliff ME, Krom BP, Meijering RA, Peters BM, Zhu JS, Scheper MA, et al. Farnesol-induced apoptosis in Candida albicans. Antimicrob Agents Chemother. 2009; 53: 2392-401.
30. Wissing S, Ludovico P, Herker E, Büttner S, Engelhardt SM, Decker T, et al. An AIF orthologue regulates apoptosis in yeast. J Cell Biol. 2004; 166: 969-74.
31. Phillips AJ, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in Candidaalbicans. Proc Natl Acad Sci USA. 2003; 100: 14327-32.
32. Phillips AJ, Crowe JD, Ramsdale M. Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candidaalbicans. Proc Natl Acad Sci USA. 2006; 103: 726-31.
33. Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet. 2009; 43: 95-118.
34. Pozniakovsky AI, Knorre DA, Markova OV, Hyman AA, Skulachev VP, Severin FF. Role of mitochondria in the pheromone- and amiodarone-induced programmed cell death of yeast. J Cell Biol. 2005; 168: 257-69.
35. Liang Q, Zhou B. Copper and manganese induce yeast apoptosis via different pathways. Mol Biol Cell. 2007; 18: 4741-9.
36. + efflux. Antimicrob Agents Chemother. 2008; 52: 4081-8.
37. Madeo F, Herker E, Wissing S, Jungwirth H, Eisenberg T, Fröhlich KU. Apoptosis in yeast. Curr Opin Microbiol. 2004; 7: 655-60.
38. Ramsdale M. Programmed cell death in pathogenic fungi. Biochim Biophys Acta. 2008; 1783: 1369-80.